摘要
目的探讨阿立哌唑治疗氟哌啶醇所致女性高催乳素血症的疗效及安全性。方法将60例氟哌啶醇所致高催乳素血症的女性精神分裂症患者,随机分为两组,在维持原氟哌啶醇治疗的同时,分别加阿立哌唑(30例)及安慰剂(30例)治疗,疗程6周。分别于治疗前、治疗6周末检测血清催乳素(PRL)水平、评定简明精神病量表(BPRS)及副反应量表(TESS),同时观察高催乳素血症临床症状变化情况。结果1治疗6周末,阿立哌唑组PRL26.1±9.4μg/L较治疗前99.4±31.3μg/L下降(P=0.000),安慰剂组PRL91.3±38.3μg/L与治疗前96.9±30.8μg/L无显著性差异(P=0.230);2治疗6周末,阿立哌唑组PRL下降值73.2±27.2μg/L高于安慰剂组5.7±25.3μg/L,差异有显著性(P=0.000);3两组不良反应总体发生率均低,对原氟哌啶醇治疗的疗效均无不良影响。结论阿立哌唑可安全、有效治疗氟哌啶醇所致的女性高催乳素血症。
Objective To explore the efficacy and tolerability of aripiprazole in the treatment of female hyperprolactinemia by haloperidol.Methods 60 female schizophrenic patients with hyperprolactinemia by haloperidol were randomly assigned to aripiprazole group（n=30）and placebo group（n=30）for 6 weeks,while receiving antipsychotics treatment.The prelactin（PRL）was measured at the baseline and the end of study,same as the clinical symptoms of hyperprolactinemia were evaluated.The adverse effects on original antipsychotics treatment and other side effects were assessed with the Brief Psychiatric Rating Scale（BPRS） and the Treatment Emergent Symptom Scale（TESS） before and after the study.Results ①The concentration of PRL was lower after the study（26.1±9.4μg/L）than before the study（99.4±31.3μg/L）in aripiprazole group,and the difference was statistically significant（P=0.000）,however this difference in placebo group wasnot statistically significant before and after the study（P=0.230）.②At the end of 6th week,the concentration of PRL was dropping（73.2±27.2μg/L）in aripiprazole group,which was higher than the placebo group（5.7±25.3μg/L） and the difference was statistically significant（P=0.000）.③The total prevalence of side effects was low in both groups,and no adverse effects on original antipsychotics treatment were recored in any group.Conclusion Aripiprazole is effective and safe in the treatment of female hyperprolactinemia by haloperidol.
出处
《中国健康心理学杂志》
2009年第2期194-195,共2页
China Journal of Health Psychology
